Oncotelic Therapeutics (OTCQB: OTLC), together with its wholly owned subsidiary Pet2DAO, Inc., announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers and biotech founders to participate in BIO REBOOT. Participants can bring research questions, technical expertise and drug discovery ideas to the PDAOAI community, with selected projects potentially considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning and clinical development.
Oncotelic also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, taking place Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study illustrating how Partitioned Literature Aggregation generated a candidate four-gene signature, while Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development.
To view the full press release, visit https://nnw.fm/2KpxY
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer